Cyclacel Pharmaceuticals Inc (CYCC) Quote

CYCC 10Q due 3/19

while s. robotis has certainly got to be in the running for longest serving, worst performing CEO of any American company
in history, one has to admire that decade after decade he is able to draw a sizeable paycheck, while keeping his
handpicked and doubtlessly corrupt bod in his back pocket. he could teach a valuable course at any business school.
what a great subject for a great novel cycc and it's unapologetic, feckless leader would make.
go Spiro go--and you know he will do just that!

CYCC new 52 week low

how has Spiro kept his job?
is there a functioning board of directors?
he's been drawing a big salary without a single thing for an investor to feel good about for so many years. ??????

CYCC.......................................https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783

CYCC new 52. Week low

CYCC new 52 week low

CYCC new 52 week low

CYCC............................https://stockcharts.com/h-sc/ui?s=CYCC&p=W&b=5&g=0&id=p86431144783

Nice buy

Sar Pas,

No reply to my last post! The stock is now at 73 cents. Get out while you can. It is not on fire! I can't beleive that you have not responded.

He is a scammer and it will soon be delisted or he will have to do another offering. I lost thousands years ago. It is what Spiro does. He keeps on sucking in new money so that he can live the life of luxury while we all lose our shirts. That is what he does. Everyone needs to run as fast as possible and take their loses. This guy and his board should be shut down. I can't stand to see what you are all going through! Get out Now!

So what do you have to say now? Spiro has been sucking in people for years. Prepare yourself for another reverse split so that he can keep the money rolling in. I lost thousands years ago. He is a scammer! Run!

Ihub is a valueless waste land

Stock is on fire in PM and nobody to comment ? Closed at $1.31 and was up to $1.99 in PM. Wake up people.

That was nice :) moving on.

This should be the week. See what the universe delivers on this opp. It does what it wants.

spiro rombotis. not just in the usa, but globally, he would be right at the
very top of highest paid, longest standing, and worst ceos. can't even imagine
how corrupt the board is. if he has family, not even they would've let him
keep his job. he's smart, he's very articulate, hard to imagine a bigger fraudster.
if cycc wasn't what it is, he would've been out 10 years ago. or more...

Nobody needs to be in here now. But ya’ll will be checking in here later cause we gonna blow this up

Movement PM

Enter ar 3,80, bullish by TA, regards

AH boom

just the fact that spiro and his cohort, i mean cfo, have had
their ludicrous contracts extended is enough to drop the value
of the company almost by 1/5th. the bod of cycc, they must be
some bunch. spiro, he's almost too bad to be true. smart? he is that. deserving to keep his job? oh lord love a duck. even if he
paid himself nothing instead of the ludicrous salary he is paid
he should've been ousted many years ago...

We find stuff like CYCC and, unlike the the "mud merchant" we tell you about them BEFORE they pop. This way, you've got a chance to make money and not just be sitting there after the explosion watching a video of some guy drawing arbitrary lines and pontificating about the stock might go up or it might go down.

This chart was looking fantastic June of last year.

Highs are good

CYCC hit Another New high $4.45 so far! It is heading onto $4.68 now since the Bottom was $3.12...

Another New high $4.34 today! CYCC is heading onto $20 again...

CYCC is much much much cheaper than all its COVID-19 peers now!

I hope the price stabilizes, 3 - 4$

CYCC just hit a New high $4.35 in the Pre-Market session of today! We should see $6 again as soon as tomorrow...

To replicate the Same 7.413-Bagger Strong performance with its NASDAQ-peer (HUSA), CYCC will surge to $23.13 which is 5.74 Times of its current ridiculous low price $4.03!

nice

CYCC hit $4.19 today! We should see $6 again as soon as this week...

Super Undervalued now! Hyper Oversold --- from nearly $20 to $3.12!

CYCC ~ looks okay

Yes, CYCC bounced to $3.98 today! We should see it soar back to $20 again before the end of 2020 since the company is developing COVID-2019 related hot drugs...

CYCC has Very Good News after the market close --- no more share's dilution to raise the cash till 12/31/2022!

CYCC has $4.76 per share Cash Value and $5.03 per share Book Value now!

So it is Extremely Undervalued currently! At Hyper Oversold status now --- from $19.xx to $3.12!

Thus it will Quickly And Easily surge back to its most recent high $19.xx (i.e. nearly $20) again...

CYCC might replicate 7.143-Bagger Quick rally to hit $22.29 like its NASDAQ-peer (HUSA) did!

will move up some

Yes, CYCC seems Bottomed out at $3.19! It bounced to $4.25 so far! Easy to surge back to $6.00 again since its most recent high was nearly $20.00...

north is good

Can CYCC test its most recent high $6.00 in the next week?

CYCC should run in the next week unless any bad news kicks in...

Hyper Oversold --- from $20.xx to $3.23?

CYCC has bounced to $3.87 so far from the New Bottom $3.23!

will announce second quarter 2020 financial results on Wednesday, August 12, 2020. The Company will host a conference call and live webcast at 4:30 p.m

3-4 catalyst awaiting this year for this thing, I would not doubt we will be trading in the teens soon before the end of the year, especially the news regarding their COVID phase in Scotland.

Riding the waves !

News very soon.

News pending thus the move.

Breakout watch

Should get news soon.

Cyclacel ’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer

2020-07-13 07:00 ET - News Release

-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against

CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC –

-- Data builds on growing body of evidence indicating the promise of dual CDK2/9 inhibition --

BERKELEY HEIGHTS, N.J. and DUNDEE, United Kingdom, July 13, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced publication of a peer-reviewed study of fadraciclib, in PLOS ONE. The publication, authored by scientists from Cyclacel and The Institute of Cancer Research, London, describes the discovery of fadraciclib and shows its ability to target CDK2 and CDK9, leading to broad therapeutic potential.

“The published findings strengthen the mechanistic rationale for fadraciclib’s potential as an anti-cancer therapy. Building upon previous research in CDK pathways, including the roles of cyclin E, MCL1 and MYC overexpression, the paper highlights the benefits of inhibiting both CDK2 and CDK9, two complementary cancer pathways,” said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. “Independent findings reported at the ASCO20 Virtual Scientific Program corroborate the attractiveness of this dual targeting approach. Based on recently disclosed clinical data fadraciclib is establishing a leadership position among apoptosis enabling compounds in clinical development. We are encouraged by observations of single agent anticancer activity in our clinical studies. Initial clinical data with oral fadraciclib show concordance with intravenous pharmacokinetics. In parallel with evaluating fadraciclib in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS), we are executing a precision medicine strategy to evaluate fadraciclib in patients with solid tumors, with study enrollment expected to begin by Q1 2021.”

“These exciting new findings revealing fadraciclib’s chemical structure and describing its relevant anti-cancer properties, reflect the highly productive collaboration of ICR with Cyclacel to discover and develop innovative cancer treatments,” said Professor Paul Workman, FMedSci, FRS, study co-author and Chief Executive and President, The Institute of Cancer Research, London, UK. “As a potent and selective inhibitor of CDK2 and CDK9, we believe our cumulative findings to-date support fadraciclib’s ability to address key cancer pathways in solid tumors and leukaemias, indicating its potential as a new targeted anti-cancer therapy.”

Cyclin-dependent kinases (CDKs) exist in many isoforms and as key cell cycle regulators can play a critical role in cancer growth. This preclinical characterization of fadraciclib includes its potency and selectivity against CDK2 and CDK9 in vitro and in a broad range of cancer cell lines including AML, breast and colorectal. Further in vivo efficacy was demonstrated in leukemia xenograft models.

Experimental results support fadraciclib’s anti-cancer activity through CDK2/9 inhibition. In breast cancer cell lines, short-pulse treatment with fadraciclib showed preferential activity against transformed cells over normal cells. This finding supports the compound’s potential benefit in cancers addicted to cyclin E which can be rationally targeted by CDK2 inhibition. In AML models, fadraciclib was effective in inhibiting CDK9 and suppressing the MCL1 protein to induce apoptosis or programmed cell death of leukemia cells. Fadraciclib also demonstrated synergy with BCL2 inhibitors such as venetoclax in AML cells. In subcutaneous mouse xenograft models of AML and MLLr-AML, nearly 100% tumor growth inhibition was achieved with oral administration of fadraciclib at pharmacological doses.

Keep on selling me cheapies

Ill take em $4.35 thanks